Clinical Trials on Hypercholesterolemia in Hong Kong

Total 28 results

Chinese University of Hong Kong

Completed

Genome-wide Analysis of Lipid-lowering Efficacy and Drug Level of Simvastatin and Rosuvastatin

Hypercholesterolemia

Hong Kong
Novartis Pharmaceuticals

Completed

A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH) (ORION-5)

Homozygous Familial Hypercholesterolemia

Hong Kong, Israel, Russian Federation, Serbia, South Africa, Taiwan, Turkey, Ukraine
Amgen

Completed

Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities (TESLA)

Homozygous Familial Hypercholesterolemia

New Zealand, South Africa, France, United States, Spain, Belgium, Czechia, Italy, Netherlands, Hong Kong, Canada, Lebanon
AstraZeneca

Completed

DISCOVERY Asia - Crestor in Type IIa and IIb Hypercholesteremia

Hypercholesterolemia

China, Taiwan, Malaysia, Hong Kong, Korea, Republic of, Thailand
Amgen

Completed

Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders (TAUSSIG)

Severe Familial Hypercholesterolemia

Italy, Czechia, United States, Israel, New Zealand, South Africa, France, Spain, Australia, Belgium, Canada, Netherlands, Hong Kong, Brazil, United Kingdom, Greece, Japan, Lebanon
Amgen

Completed

Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2 (RUTHERFORD-2)

Hyperlipidemia

Canada, France, Netherlands, United Kingdom, New Zealand, South Africa, Spain, United States, Australia, Germany, Sweden, Hong Kong, Switzerland, Norway
Novartis Pharmaceuticals

Active, not recruiting

Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol. (V-Mono China)

Primary Hypercholesterolemia or Mixed Dyslipidemia

China
Merck Sharp & Dohme LLC

Recruiting

MK-0616 (Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

Arteriosclerosis | Hypercholesterolaemia

United States, Taiwan, Canada, Israel, New Zealand, Hong Kong, Argentina, Korea, Republic of, Turkey, Australia, Chile, Brazil, Japan, Colombia, China, United Kingdom
AstraZeneca

Completed

Centralized Pan-Asian Survey on the Under Treatment of Hypercholesterolemia (CEPHEUS)

Hypercholesterolemia

Korea, Republic of, Vietnam, Malaysia, Taiwan, Philippines, China, Indonesia, Thailand
Takeda

Terminated

Efficacy of Lapaquistat Acetate in Subjects With Hypercholesterolemia

Hypercholesterolemia

United States
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of MK-0616 (Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017) CORALreef HeFH

Hypercholesterolemia | Familial Hypercholesterolemia

United States, Australia, Brazil, Canada, Chile, Colombia, Czechia, Finland, Hong Kong, Hungary, Israel, Netherlands, New Zealand, Norway, Singapore, Spain, Taiwan
Pfizer

Completed

A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins

Dyslipidemia | Hypercholesterolemia

United States, Canada
AstraZeneca

Completed

Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol ("Bad Cholesterol") and Triglycerides

Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia

United States
Kastle Therapeutics, LLC

Completed

A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol (FOCUS FH)

Hypercholesterolemia | Heterozygous Familial

United States, Italy, Poland, Ukraine, United Kingdom, Germany, Hong Kong, Taiwan, Spain, Argentina, Belgium, Israel, Malaysia, South Africa, Turkey, Netherlands, Korea, Republic of, Canada, New Zealand, Russian Federation, Brazil, Austral... and more
Amgen

Completed

Open Label Study of Long Term Evaluation Against LDL-C Trial (OSLER)

Hypercholesterolemia

United States, Denmark, Finland, Czechia, Hungary, South Africa, Spain, Australia, Belgium, Canada, Netherlands, Germany, Sweden, Hong Kong, Japan, Singapore, United Kingdom, Norway
Esperion Therapeutics, Inc.
Medpace, Inc.

Completed

Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients

Hypercholesterolemia

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy (ODYSSEY FH I)

Hypercholesterolemia

United States, Austria, Canada, Czech Republic, Denmark, France, Israel, Netherlands, Norway, Russian Federation, South Africa, Spain, Sweden, United Kingdom
Takeda

Completed

Efficacy of Lapaquistat Acetate Alone or Combined With Simvastatin in Subjects With Hypercholesterolemia

Hypercholesterolemia

United States, Canada
Takeda

Completed

Efficacy of Lapaquistat Acetate Alone or Combined With Rosuvastatin in Subjects With Hypercholesterolemia

Hypercholesterolemia

United States, Canada
Takeda

Terminated

Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia

Hypercholesterolemia

United States
Amgen

Completed

Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab

Hypercholesterolemia

Canada, Netherlands, Spain, Belgium, United States, Russian Federation, Czechia, Mexico, Korea, Republic of, Australia, United Kingdom, Argentina, Israel, France, Hungary, Germany, Greece, Poland, Switzerland, Italy, Brazil, Sweden, Norwa... and more
AstraZeneca

Completed

A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia

Dyslipidemia | Hypercholesterolemia

United States
AstraZeneca

Withdrawn

Effect of an Internet Based Compliance Enhancement Tool in Subjects With Hypercholesterolemia

Hypercholesterolemia

Denmark
Sanofi
Regeneron Pharmaceuticals

Completed

Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

Hypercholesterolemia

Sweden, Germany, Russian Federation, Denmark, Israel, South Africa, Spain, Hungary, United States, Colombia, Czech Republic, Argentina, Belgium, Bulgaria, Canada, Chile, Finland, France, Italy, Mexico, Netherlands, Norway, Poland, Por... and more
Amgen

Completed

GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound (GLAGOV)

Hypercholesterolemia

United States, Canada, Denmark, Germany, Italy, Netherlands, Spain, Sweden, Belgium, Taiwan, Russian Federation, France, Czechia, Mexico, Korea, Republic of, Australia, United Kingdom, Argentina, Israel, Hungary, South Africa, Greece and more
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-0616 (Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids

Hypercholesterolemia | Familial Hypercholesterolemia

United States, Taiwan, Israel, Argentina, Japan, Korea, Republic of, Turkey, Colombia, China, Mexico, Germany, Italy, South Africa, Spain
Esperion Therapeutics, Inc.

Completed

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant (CLEAR Serenity)

Hypercholesterolemia | Atherosclerotic Cardiovascular Disease | Statin Adverse Reaction

United States, Canada
Furiex Pharmaceuticals, Inc

Completed

Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)

Myalgia | Hypercholesterolemia | Hyperlipidemia

United States

Clinical Trials on Hypercholesterolemia in Hong Kong

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations